This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Skali, H. Articles by Pfeffer, M. A Search for Related Content PubMed PubMed Citation Articles by Skali, H. Articles by Pfeffer, M. A Pubmed/NCBI databases Medline Plus Health Information Blood Pressure Medicines Clinical Trials High Blood Pressure Social Bookmarking                         What's this?

Review: Prospects for ARB in the next five years

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Marc A Pfeffer

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, mpfeffer@ rics.bwh.harvard.edu

Key Words: angiotensin II antagonists • angiotensin-converting enzyme inhibitors • clinical trials

References

• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.[Abstract]
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.N Engl J Med 1991;325:293-302.[Abstract]
• Pfeffer MA, Braunwald E., Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.[Abstract]
• Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-8.[Web of Science][Medline] [Order article via Infotrieve]
• Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-6.[Abstract/Free Full Text]
• Kober L.,Torp-Pedersen C., Carlsen JE et al.A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. NEnglJMed 1995;333:1670-6.[Abstract/Free Full Text]
• Yusuf S., Lonn E., Bosch J., Gerstein H. Summary of randomized trials of angiotensin converting enzyme inhibitors. Clin Exp Hypertens 1999;21:835-45.[Web of Science][Medline] [Order article via Infotrieve]
• Flather MD,Yusuf S., Kober L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.[Abstract/Free Full Text]
• Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.Lancet 2001;358:1033-41. 11. Burnier M., Brunner HR Angiotensin II receptor antagonists. Lancet 2000;355:637-45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - The Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pitt B., Segal R., Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dickstein K., Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 1999;83:477-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pfeffer MA, McMurray J., Leizorovicz A. et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Carson PE Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. Am Heart J 2000;140:361-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dickstein K., Chang P., Willenheimer R. et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. JAm Coll Cardiol 1995;26:438-45.[Abstract]
• Di Pasquale P., Bucca V., Scalzo S., Paterna S. Safety, tolerability, and neurohormonal changes of the combination captopril plus losartan in the early postinfarction period: a pilot study. Cardiovasc Drugs Ther 1998;12:211-16.[Web of Science][Medline] [Order article via Infotrieve]
• Hamroff G., Katz SD, Mancini D. et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999;99:990-2.[Abstract/Free Full Text]
• Cohn JN, Tognoni G., the Valsartan Heart Failure Trial Investigators. A Randomized Trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.[Abstract/Free Full Text]
• Cohn JN, Tognoni G., Glazer R., Spormann D. Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. Eur J Heart Fail 2000;2:439-46.[Abstract/Free Full Text]
• Swedberg K., Pfeffer M., Granger C. et al. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.J Card Fail 1999;5:276-82.[CrossRef][Medline] [Order article via Infotrieve]
• Bart BA, Ertl G., Held P. et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999;20:1182-90.[Abstract/Free Full Text]
• Dahlof B., Devereux R., de Faire U. et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997;10:705-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mann J., Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7:176-83.
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
• Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.NEnglJMed 2001;345:861-9.[Abstract/Free Full Text]
• Parving HH, Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
• Hansson L., Lithell H., Skoog I. et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999;8:177-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 4, 215-218 (2001)
DOI: 10.3317/jraas.2001.034


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. J.V. McMurray, M. A. Pfeffer, K. Swedberg, and V. J. Dzau Which Inhibitor of the Renin-Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? Circulation, November 16, 2004; 110(20): 3281 - 3288. [Full Text] [PDF]

				M. A. Pfeffer, J. J.V. McMurray, E. J. Velazquez, J.-L. Rouleau, L. Kober, A. P. Maggioni, S. D. Solomon, K. Swedberg, F. Van de Werf, H. White, et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both N. Engl. J. Med., November 13, 2003; 349(20): 1893 - 1906. [Abstract] [Full Text] [PDF]

				M.A. Pfeffer The intersection between acute coronary syndrome and heart failure Eur. Heart J. Suppl., April 1, 2003; 5(suppl_C): C19 - C23. [Abstract] [PDF]

This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Skali, H. Articles by Pfeffer, M. A Search for Related Content PubMed PubMed Citation Articles by Skali, H. Articles by Pfeffer, M. A Pubmed/NCBI databases Medline Plus Health Information Blood Pressure Medicines Clinical Trials High Blood Pressure Social Bookmarking                         What's this?